AKT1 and lung carcinoma: Moreover, PTPN11 confers cisplatin resistance to lung cancer cells through activation of the AKT-CA916798 pathway and the Ras/phosphoinositide 3-kinase (PI3K)/AKT1/survivin pathway, respectively (47, 48).